Skip to content

US · ABSI · BIOTECHNOLOGY

Absci Corporation (ABSI) intrinsic value and stock valuation

$7.51as of 2026-11-21 · Mkt cap 1.42B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Absci Corporation DCF and intrinsic value

InvestorsCraft values ABSI with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ABSI’s statements →

Absci Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Vancouver, WA 98683 absci.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$2.8M-10.1% 5y CAGRd
20192025
Net income
-$-115.18M
20192025
Free cash flow
-$-94.03M
20192025
Total equity
$189.5M+23.1% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$2.8M$4.53M$5.72M$5.75M$4.78M
Operating income-$-124.72M-$-108.89M-$-115.52M-$-106.75M-$-75.24M
Net income-$-115.18M-$-103.11M-$-110.57M-$-104.9M-$-100.96M
EPSd-$-842.08K-$-935.32K-$-1.2M-$-1.15M-$-1.09M
Operating cash flow-$-92.92M-$-72.4M-$-64.64M-$-81.34M-$-60.6M
Capital expenditure-$-1.11M-$-400K-$-860K-$-16.18M-$-38.05M
Free cash flow-$-94.03M-$-72.81M-$-65.5M-$-97.51M-$-98.64M
Total assets$216.3M$213.6M$217.3M$321M$426.2M
Total debt$5.3M$10.1M$15.9M$23M$20M
Net debt-$-14.72M-$-31.11M-$-56.48M-$-36.97M-$-232.56M
Total equity$189.5M$179.1M$176.2M$274.4M$366.1M
Cash and short-term investments$144.3M$112.4M$97.7M$164.4M$252.6M
Income statement
20252024202320222021
Revenue$2.8M$4.53M$5.72M$5.75M$4.78M
Cost of revenue$11.7M$62.5M$47.6M$58.9M$44.6M
Gross profit-$-8.94M-$-57.92M-$-41.85M-$-53.16M-$-39.8M
Research and development expenses$81.4M$63.9M$48.1M$58.9M$44.6M
Selling, general and administrative expenses$35.1M$0.00$0.00$0.00$0.00
Other expenses-$-700K-$-12.9M$25.6M-$-5.32M-$-9.15M
Operating expenses$115.8M$51M$73.7M$53.6M$35.4M
Cost and expenses$127.5M$113.4M$121.2M$112.5M$80M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$210K$560K$1.01M$970K$3.43M
Depreciation and amortization$11.7M$13.4M$14M$13M$6.65M
Ebitda-$-103.16M-$-94.1M-$-79.68M-$-91.36M-$-67.68M
Operating income-$-124.72M-$-108.89M-$-115.52M-$-106.75M-$-75.24M
Total other income/expenses, net$9.6M$5.85M$5.05M$1.39M-$-34.62M
Income before tax-$-115.11M-$-103.04M-$-110.47M-$-105.36M-$-109.86M
Income tax expense$70K$70K$100K-$-460K-$-8.9M
Net income-$-115.18M-$-103.11M-$-110.57M-$-104.9M-$-100.96M
Weighted average shares outstanding$136.8M$110.2M$92M$90.9M$92.7M
Weighted average diluted shares outstanding$136.8M$110.2M$92M$90.9M$92.7M
Balance sheet
20252024202320222021
Cash and short-term investments$144.3M$112.4M$97.7M$164.4M$252.6M
Net receivables$0.00$0.00$2.19M$1.55M$1.43M
Inventory$0.00$0.00$0.00$15M$10.5M
Total current assets$149.6M$133.8M$120.6M$186.9M$273.1M
Property, plant and equipment, net$23.8M$33.1M$45.8M$58M$58.7M
Goodwill and intangible assets$41.5M$44.9M$48.3M$73M$76.3M
Long-term investments$0.00$0.00$0.00$1.86M$16.8M
Total non-current assets$66.7M$79.8M$96.7M$134.2M$153.1M
Total assets$216.3M$213.6M$217.3M$321M$426.2M
Accounts payable$2.76M$3.53M$1.5M$2.41M$8.38M
Short-term debt$2.68M$4.42M$5.58M$6.93M$6.69M
Deferred revenue$740K$1.12M$3.17M$450K$1.35M
Total current liabilities$22.8M$28.7M$29.6M$30.3M$33.9M
Long-term debt$2.62M$5.69M$10.3M$16.1M$13.3M
Deferred revenue, non-current$440K$0.00$970K$0.00$0.00
Total non-current liabilities$4.08M$5.82M$11.6M$16.3M$26.2M
Capital lease obligations$4.43M$6.12M$7.96M$12.1M$16.5M
Total liabilities$26.9M$34.5M$41.1M$46.6M$60.1M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-624.78M-$-509.6M-$-406.5M-$-295.93M-$-191.03M
Accumulated other comprehensive income (loss)$590K-$0.00-$-40K-$-120K-$-10K
Total equity$189.5M$179.1M$176.2M$274.4M$366.1M
Total investments$124.3M$71.2M$25.3M$106.3M$16.8M
Total debt$5.3M$10.1M$15.9M$23M$20M
Net debt-$-14.72M-$-31.11M-$-56.48M-$-36.97M-$-232.56M
Cash flow statement
20252024202320222021
Net income-$-115.18M-$-103.11M-$-110.57M-$-104.9M-$-100.96M
Depreciation and amortization$11.7M$13.4M$14M$13.1M$6.65M
Stock-based compensation$18.3M$19.5M$11.4M$12.5M$10.6M
Change in working capital$420K-$-370K$1.52M-$-1.54M-$-3.15M
Accounts receivable$0.00$2.24M-$-670K-$-150K$230K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.09M$2.03M-$-790K-$-530K$1.57M
Net cash provided by operating activities-$-92.92M-$-72.4M-$-64.64M-$-81.34M-$-60.6M
Investments in property, plant and equipment-$-1.11M-$-400K-$-860K-$-16.18M-$-38.05M
Acquisitions, net$1.31M$0.00$0.00-$-8M-$-28.13M
Net cash used for investing activities-$-50.16M-$-41.58M$81.9M-$-126.98M-$-67.38M
Common stock issued$109.1M$86.6M$860K$660K$210.4M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$106M$82.5M-$-4.48M$5.24M$336.2M
Net change in cash-$-37.14M-$-31.45M$12.8M-$-203.08M$208.2M
Cash at end of period$21.1M$58.2M$89.7M$76.8M$279.9M
Operating cash flow-$-92.92M-$-72.4M-$-64.64M-$-81.34M-$-60.6M
Capital expenditure-$-1.11M-$-400K-$-860K-$-16.18M-$-38.05M
Free cash flow-$-94.03M-$-72.81M-$-65.5M-$-97.51M-$-98.64M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Absci Corporation

        Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.

        CEO
        Sean McClain
        Employees
        140
        Beta
        2.33

        Explore

        Frequently asked questions

        What is the intrinsic value of Absci Corporation (ABSI)?

        Absci Corporation (ABSI) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ABSI undervalued?

        ABSI trades at a price of $7.51 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.